Literature DB >> 12787063

Cyclosporin A prevents calpain activation despite increased intracellular calcium concentrations, as well as translocation of apoptosis-inducing factor, cytochrome c and caspase-3 activation in neurons exposed to transient hypoglycemia.

Michel Ferrand-Drake1, Changlian Zhu, Gunilla Gidö, Anker J Hansen, Jan-Olof Karlsson, Ben A Bahr, Naoufal Zamzami, Guido Kroemer, Pak H Chan, Tadeusz Wieloch, Klas Blomgren.   

Abstract

Blockade of mitochondrial permeability transition protects against hypoglycemic brain damage. To study the mechanisms downstream from mitochondria that may cause neuronal death, we investigated the effects of cyclosporin A on subcellular localization of apoptosis-inducing factor and cytochrome c, activation of the cysteine proteases calpain and caspase-3, as well as its effect on brain extracellular calcium concentrations. Redistribution of cytochrome c occurred at 30 min of iso-electricity, whereas translocation of apoptosis-inducing factor to nuclei occurred at 30 min of recovery following 30 min of iso-electricity. Active caspase-3 and calpain-induced fodrin breakdown products were barely detectable in the dentate gyrus and CA1 region of the hippocampus of rat brain exposed to 30 or 60 min of insulin-induced hypoglycemia. However, 30 min or 3 h after recovery of blood glucose levels, fodrin breakdown products and active caspase-3 markedly increased, concomitant with a twofold increase in caspase-3-like enzymatic activity. When rats were treated with neuroprotective doses of cyclosporin A, but not with FK 506, the redistribution of apoptosis-inducing factor and cytochrome c was reduced and fodrin breakdown products and active caspase-3 immuno-reactivity was diminished whereas the extracellular calcium concentration was unaffected. We conclude that hypoglycemia leads to mitochondrial permeability transition which, upon recovery of energy metabolism, mediates the activation of caspase-3 and calpains, promoting cell death.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12787063     DOI: 10.1046/j.1471-4159.2003.01794.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  17 in total

Review 1.  Multifunctional drugs for head injury.

Authors:  Robert Vink; Alan J Nimmo
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

2.  Establishing a Clinically Relevant Large Animal Model Platform for TBI Therapy Development: Using Cyclosporin A as a Case Study.

Authors:  Susan S Margulies; Todd Kilbaugh; Sarah Sullivan; Colin Smith; Kathleen Propert; Melissa Byro; Kristen Saliga; Beth A Costine; Ann-Christine Duhaime
Journal:  Brain Pathol       Date:  2015-05       Impact factor: 6.508

3.  Influence of duration of focal cerebral ischemia and neuronal nitric oxide synthase on translocation of apoptosis-inducing factor to the nucleus.

Authors:  X Li; M Nemoto; Z Xu; S-W Yu; M Shimoji; S A Andrabi; J-F Haince; G G Poirier; T M Dawson; V L Dawson; R C Koehler
Journal:  Neuroscience       Date:  2006-10-13       Impact factor: 3.590

Review 4.  Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?

Authors:  Niklas Marklund; Lars Hillered
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

5.  Cyclosporine-A induces endoplasmic reticulum stress and influences pro-apoptotic factors in human gingival fibroblasts.

Authors:  Suresh Ranga Rao; Shiyamali Sundararajan; Rajasekaran Subbarayan; Dinesh Murugan Girija
Journal:  Mol Cell Biochem       Date:  2017-03-21       Impact factor: 3.396

6.  Cyclosporin A preserves mitochondrial function after traumatic brain injury in the immature rat and piglet.

Authors:  Todd J Kilbaugh; Sunita Bhandare; David H Lorom; Manda Saraswati; Courtney L Robertson; Susan S Margulies
Journal:  J Neurotrauma       Date:  2011-04-12       Impact factor: 5.269

7.  DNase activation by hypoxia-acidosis parallels but is independent of programmed cell death.

Authors:  John W Thompson; Regina M Graham; Keith A Webster
Journal:  Life Sci       Date:  2012-04-13       Impact factor: 5.037

8.  Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial.

Authors:  Anna Teresa Mazzeo; Gretchen M Brophy; Charlotte B Gilman; Oscar Luís Alves; Jaime R Robles; Ronald L Hayes; John T Povlishock; M Ross Bullock
Journal:  J Neurotrauma       Date:  2009-12       Impact factor: 5.269

9.  Comparative neuroprotective effects of cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury.

Authors:  Lamin H A N Mbye; Indrapal N Singh; Kimberly M Carrico; Kathryn E Saatman; Edward D Hall
Journal:  J Cereb Blood Flow Metab       Date:  2008-08-20       Impact factor: 6.200

10.  Combination therapies for traumatic brain injury: prospective considerations.

Authors:  Susan Margulies; Ramona Hicks
Journal:  J Neurotrauma       Date:  2009-06       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.